What Orthofix Spinal Kinetics refers to
Orthofix Spinal Kinetics is best read as the acquisition and product story behind the M6 artificial disc family. Orthofix completed its acquisition of Spinal Kinetics on April 30, 2018, adding the M6-C artificial cervical disc and M6-L artificial lumbar disc to its spine portfolio. The M6-C later received FDA premarket approval on February 6, 2019, for a defined single-level cervical indication from C3 to C7. The story changed in 2025, when Orthofix said it would discontinue the M6-C and M6-L product lines to concentrate resources on spinal fixation and deformity correction while continuing post-market responsibilities. For readers following spinal devices, the case is useful because it ties product design, clinical evidence, regulatory follow-up, and portfolio strategy into one timeline.
This article is an industry analysis, not patient-specific medical advice. Patients with an implanted cervical disc should follow the instructions of their surgeon, local regulator, and implanting hospital, especially if they develop new neck pain, arm symptoms, weakness, balance changes, or other unexpected symptoms.
A concise timeline of the M6 artificial disc business
| Date | Event | Why it matters |
|---|---|---|
| 2003 | Spinal Kinetics was founded as a privately held spine device company. | The company focused on motion preservation systems for degenerative spinal disease. |
| 2006 | The M6 artificial disc technology began international use, according to Orthofix materials published later. | This gave the platform a long non-U.S. commercial history before U.S. approval. |
| March 15, 2018 | Orthofix announced an agreement to acquire Spinal Kinetics. | The deal terms included $45 million in cash closing consideration plus up to $60 million in contingent milestone payments. |
| April 30, 2018 | Orthofix completed the Spinal Kinetics acquisition. | The transaction added M6-C and M6-L to Orthofix’s spine business. |
| February 6, 2019 | The FDA approved PMA P170036 for the M6-C Artificial Cervical Disc. | The approval covered a specific single-level cervical indication, not broad use across all cervical or lumbar cases. |
| November 29, 2023 | Orthofix announced publication of five-year U.S. IDE study results in The Spine Journal. | The release reported favorable five-year composite clinical success data for M6-C compared with ACDF controls. |
| February 25, 2025 | Orthofix announced a decision to discontinue the M6-C and M6-L artificial disc product lines. | The company linked the move to its focus on spinal fixation and deformity correction. |
| January 15, 2026 | The UK MHRA published device safety information on M6-C monitoring for osteolysis risk. | The notice recommended active monitoring for implanted patients in the UK context. |
| February 24, 2026 | Orthofix reported full-year 2025 results and 2026 guidance using pro forma measures that exclude discontinued M6 product lines. | M6 had become a portfolio-exit item rather than a future growth pillar. |
Why Orthofix wanted Spinal Kinetics
The original strategic logic was straightforward. In 2018, Orthofix described Spinal Kinetics as a developer and manufacturer of artificial cervical and lumbar discs. Orthofix viewed the M6 platform as a way to fill a gap in its spine fixation portfolio and enter the motion preservation segment. At the time of the acquisition agreement, M6-C and M6-L had CE Mark approval and international distribution, while M6-C was still awaiting U.S. FDA approval.
The M6 design was not simply another ball-and-socket disc. Spinal Kinetics promoted it as an attempt to mimic aspects of a natural disc through a compressible viscoelastic nucleus and a fiber annulus. Public FDA and company descriptions refer to materials such as a polycarbonate urethane core, ultra-high-molecular-weight polyethylene fibers, and titanium alloy endplates. The intended value proposition was motion preservation with controlled range of movement and shock-absorbing behavior.
That design story matters because it explains both the commercial interest and the later scrutiny. A device designed to reproduce more complex motion can give surgeons a differentiated option, but it also puts more weight on long-term wear behavior, imaging follow-up, and revision pathways. The Orthofix Spinal Kinetics case therefore became more than an acquisition note; it became a test of how motion preservation products perform across regulatory trials, real-world use, and corporate portfolio reviews.
FDA status and clinical evidence behind M6-C
The key U.S. regulatory reference is FDA PMA P170036. The FDA record names Spinal Kinetics LLC as the applicant and lists a decision date of February 6, 2019. The approval was for the M6-C Artificial Cervical Disc for reconstruction of the disc after single-level discectomy in skeletally mature patients with intractable degenerative cervical radiculopathy, with or without spinal cord compression, at one level from C3 to C7. The FDA indication also refers to patients who have failed at least six weeks of conservative treatment or have progressive neurological symptoms that could lead to permanent impairment.
Two distinctions are important. First, the U.S. PMA discussed here is for M6-C, the cervical device. Orthofix described the M6-L lumbar disc as available outside the United States, not as a U.S.-approved lumbar disc under the same PMA pathway. Second, FDA approval and commercial availability are separate matters. A device can have an approval record while a manufacturer later changes, limits, or exits commercial distribution.
The clinical evidence story includes favorable published findings. Orthofix’s 2023 announcement of five-year data from a U.S. IDE study described a prospective, multicenter, non-randomized, concurrently controlled trial at 23 U.S. sites. The reported average patient age was 44 years. At 60 months, the reported composite clinical success rate was 82.3% for M6-C patients compared with 67.0% for ACDF controls. The same announcement reported M6-C subsequent surgical intervention at 3.1%, compared with 5.3% for ACDF, and device- or procedure-related serious adverse events at 3.1%, compared with 4.8% for ACDF.
Those figures should be read as study findings, not as a universal prediction for every patient. Spine device outcomes depend on patient selection, level treated, bone quality, sagittal alignment, facet condition, surgeon experience, and follow-up duration. The M6-C evidence base can include both favorable IDE results and later post-market safety concerns; these are not contradictory by default. They come from different evidence windows.
Why the 2025 discontinuation mattered
On February 25, 2025, Orthofix announced that it would discontinue the M6-C artificial cervical disc and M6-L artificial lumbar disc product lines. The company connected the decision to strategic focus, specifically the allocation of resources and investment to spinal fixation and deformity correction. Orthofix also reported that global net sales for M6-C and M6-L were $23.4 million in 2024.
By February 24, 2026, Orthofix’s full-year 2025 results showed how the exit was being reflected financially. The company presented pro forma measures excluding the discontinued M6 product lines. In its full-year table, the impact from discontinuation of M6 product lines was $10.4 million in 2025 compared with $23.4 million in 2024, a decline of 55.4%. That presentation reinforces the point that M6 was no longer positioned as a forward growth category for Orthofix.
It is important not to overstate what discontinuation means. Based on the public materials reviewed, Orthofix framed the product-line exit as a strategic portfolio decision. The company also stated in 2025 that it intended to meet requirements related to post-market surveillance and PMA obligations, including completion of the U.S. IDE study. A commercial exit is not the same as saying every implanted device has failed, nor is it the same as an FDA revocation. It does, however, affect surgeon choice, distributor activity, inventory planning, patient questions, and the competitive opening for other cervical disc systems.
Safety signal and monitoring context
The most careful way to interpret the M6-C safety discussion is to separate regulatory approval, clinical trial performance, and post-market surveillance. Published literature has described osteolysis and revision concerns in some M6-C patients. A 2022 European Spine Journal article from an Australian clinical setting reported that 18 of 53 M6-C cervical total disc replacement patients were revised at an average of 67 months for wear-induced osteolysis. The authors characterized the midterm failure signal as concerning and recommended that patients with M6-C prostheses be contacted, informed, and assessed clinically and radiologically.
A later 2025 European Spine Journal article from the same broader research environment reported that 19 of 53 M6-C patients required revision spine surgery due to osteolysis. The paper reported that revision surgery improved neck pain, but arm pain and disability did not meet minimum clinically important difference thresholds. That finding is relevant for surgeons and device teams because it underlines the value of earlier detection and realistic counseling. Revision can be necessary and beneficial in selected cases, but it may not fully restore every patient-reported outcome. See also: Implants.
The UK MHRA added a regulatory monitoring dimension when it published device safety information on January 15, 2026. The MHRA said it assessed reports of osteolysis and early device failure in literature and advised that UK patients implanted with M6-C should be informed of osteolysis risks and receive annual routine monitoring. The notice recommended anterior-posterior and lateral cervical spine X-rays each year, with CT or MRI when symptoms or suspected osteolysis require further evaluation. It also stated that the manufacturer discontinued M6-C in February 2025 and that no M6-C devices remained available for use on the UK market.
That UK communication should not be treated automatically as a global clinical protocol, but it is a meaningful signal for the spine device field. It shows how long-term implant surveillance can become central to the life cycle of a motion preservation device, especially when wear, osteolysis, multilevel use, or revision complexity enters the evidence discussion.
What the case means for spine device strategy
The Orthofix Spinal Kinetics timeline offers several lessons for medical device companies, distributors, surgeons, and market observers.
- Differentiated biomechanics need long follow-up. A device designed to behave more like a natural disc still has to prove durability under years of loading, patient variation, and surgical technique differences.
- Regulatory approval is a milestone, not the end of evidence generation. FDA PMA approval supported the M6-C indication in 2019, but post-market data, supplements, surveillance duties, and later literature remained important.
- Commercial strategy can change even when clinical data are favorable. Orthofix’s 2025 rationale focused on portfolio concentration, margin, and resource allocation toward spinal fixation and deformity correction.
- Safety communication and corporate rationale should not be merged carelessly. Orthofix described the discontinuation as strategic, while independent literature and the MHRA discussed osteolysis monitoring. Both should be reported with attribution, without turning one into proof of the other.
- Installed patients remain part of the device life cycle. Product-line exits do not remove the need for follow-up, adverse-event reporting, surgeon education, or revision planning where clinically indicated.
For competitors, the M6 exit may create space in cervical disc replacement discussions, but it also raises the bar for long-term data transparency. For hospitals and ambulatory surgery centers, it highlights the practical importance of implant tracking, patient recall workflows, and access to imaging history. For investors, the case shows how a product with recognizable technology and meaningful sales can still be deprioritized if it no longer fits a company’s margin and growth architecture.
How to interpret the evidence without over-reading it
A balanced reading of Orthofix Spinal Kinetics requires holding several facts together. The acquisition was a strategic motion-preservation move in 2018. The M6-C achieved FDA PMA approval in 2019 for a specific cervical indication. Five-year U.S. IDE data reported favorable results versus ACDF controls on composite clinical success. Later published literature and the MHRA safety information raised attention to osteolysis monitoring and revision complexity in some implanted patients. Orthofix then moved the M6 product lines out of its future commercial focus.
None of those points should be treated as a simple verdict that the platform was either a success or a failure. The better conclusion is that spine implants are evaluated across multiple timelines: design rationale before launch, controlled trial evidence at approval, real-world performance after broad use, and corporate strategy as portfolios mature. M6-C and M6-L now serve as a case study across all four timelines.
Frequently asked questions
Did Orthofix acquire Spinal Kinetics?
Yes. Orthofix announced the agreement on March 15, 2018, and completed the acquisition on April 30, 2018. The deal brought Spinal Kinetics’ M6-C cervical and M6-L lumbar artificial disc technologies into the Orthofix spine portfolio.
Is the M6-C artificial cervical disc FDA approved?
The FDA approved PMA P170036 for M6-C on February 6, 2019, for a defined single-level cervical indication from C3 to C7 in skeletally mature patients with intractable degenerative cervical radiculopathy, with or without spinal cord compression. That approval status should be distinguished from commercial availability after Orthofix’s 2025 product-line discontinuation decision.
Was M6-L approved in the United States?
The U.S. FDA approval discussed in this article is for M6-C, the cervical disc. Orthofix public materials described M6-L, the lumbar disc, as available outside the United States. Readers should not assume that M6-C and M6-L had the same U.S. regulatory status.
Why did Orthofix discontinue the M6-C and M6-L lines?
Orthofix publicly linked the 2025 discontinuation to its strategic focus on spinal fixation and deformity correction and to allocating resources toward more profitable growth opportunities. Separate post-market literature and UK safety communication discuss osteolysis monitoring, but those should be attributed separately rather than treated as the company’s stated reason.
What should patients with an M6-C implant do?
Patients should not rely on industry articles for personal medical decisions. They should contact their implanting surgeon or hospital if they have new or unexpected symptoms and should follow any local regulator or hospital monitoring instructions. In the UK, the MHRA communication called for annual routine monitoring of patients implanted with M6-C.